Kenshi Kinoshita, director general of the Japan Pharmaceutical Manufacturers Association (JPMA), said on April 16 that escalating tensions in the Middle East have yet to have an immediate impact on drug supply, but are already pushing up raw material costs.…
To read the full story
Related Article
- JPMA Names Shionogi’s Go Takahashi as Managing Director
March 23, 2026
ORGANIZATION
- JPMA Launches New Legal Entity, Set for October Transition
May 1, 2026
- Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
April 27, 2026
- JPMA Mulls Proposal to Standardize PMDA Review Reports
April 27, 2026
- JPWA Urges Caution on Fixed Margins, Citing French Model Shortcomings
April 24, 2026
- APAC Disbands Drug Discovery WG as Asia Capabilities Rise
April 23, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





